Drug intelligence / Profile preview

Mibenratide

Development stage: Phase 2
Lead developer: Janssen Research & Development
Modality: Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
Administration: Intravenous

Overview

Mibenratide is a protein drug, specifically an 18-amino acid anti-beta1-adrenergic receptor antibody cyclic peptide. It functions as a beta-1 adrenergic receptor antagonist. Initially developed by Johnson & Johnson (Janssen Research & Development LLC), its development was discontinued at Phase 2 for indications such as heart failure.

Other names: mibenratidamibenratide [INN]MIBENRATIDE [WHO-DD]

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on Mibenratide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mibenratide.

Explore the full profile